SCHEMBL26898660

SCHEMBL26898660

CC(C)c1cccnc1C(=O)NS(N)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CHRNA7 P36544 1/20 0.40
EGLN2 Q96KS0 1/20 0.39
FTO Q9C0B1 1/20 0.39
P2RX7 Q99572 1/20 0.39
GABRA1 P14867 1/20 0.37
GABRB2 P47870 1/20 0.37
BACE1 P56817 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27021659 0.87 L3MBTL1 (0.41) ALDH1A1LMNASMN1; SMN2P2RX7
SCHEMBL26898635 0.83 BACE1 (0.38) ALDH1A1LMNASMN1; SMN2BACE1
SCHEMBL26856985 0.82 TLR7 (0.39) ALDH1A1LMNASMN1; SMN2BACE1
SCHEMBL27021671 0.81 SCN9A (0.39) ALDH1A1LMNASMN1; SMN2CHRNA7BACE1
SCHEMBL26874929 0.80 CTSA (0.37) ALDH1A1LMNASMN1; SMN2P2RX7BACE1
SCHEMBL10094241 0.80 PLK1 (0.43) ALDH1A1LMNASMN1; SMN2GABRA1GABRB2
SCHEMBL26898570 0.79 LMNA (0.44) ALDH1A1LMNASMN1; SMN2EGLN2FTO
SCHEMBL26898659 0.79 SCN9A (0.40) ALDH1A1LMNASMN1; SMN2GAAMAPT
SCHEMBL26874719 0.77 ALDH1A1 (0.48) ALDH1A1LMNASMN1; SMN2EGLN2FTO
SCHEMBL4262640 0.76 GABRA1 (0.41) ALDH1A1LMNASMN1; SMN2CHRNA7GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2024-01-18 US disclosed
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2024-01-18 US disclosed
WO-2023212693-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION (US) 2023-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 ALDH1A1 3412/4885LMNA 3204/4885SMN1; SMN2 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.